- Home
- PGNY vs PHVS Comparison
PGNY vs PHVS Comparison
Compare PGNY & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGNY | PHVS |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PGNY | PHVS |
|---|---|---|
| Price | $24.76 | $27.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $27.90 | ★ $39.44 |
| AVG Volume (30 Days) | ★ 1.4M | 199.4K |
| Earning Date | 02-26-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.96 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $1,268,689,000.00 | N/A |
| Revenue This Year | $11.63 | N/A |
| Revenue Next Year | $9.52 | N/A |
| P/E Ratio | $40.86 | ★ N/A |
| Revenue Growth | ★ 11.41 | N/A |
| 52 Week Low | $17.98 | $11.51 |
| 52 Week High | $28.75 | $29.80 |
Technical Indicators
Market Signals| Indicator | PGNY | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 59.14 |
| Support Level | $24.62 | $26.90 |
| Resistance Level | $25.78 | $28.50 |
| Average True Range (ATR) | 1.18 | 1.38 |
| MACD | -0.22 | 0.22 |
| Stochastic Oscillator | 16.75 | 81.00 |
Price Performance
Historical ComparisonAbout PGNY Progyny Inc.
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.